Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

被引：50

作者：

Cheng, Ying ^{[1
]}

Chen, Jianhua ^{[2
]}

Zhang, Wei ^{[3
]}

Xie, Chao ^{[4
]}

Hu, Qun ^{[5
]}

Zhou, Ningning ^{[6
]}

Huang, Chun ^{[7
]}

Wei, Shihong ^{[8
]}

Sun, Hong ^{[9
]}

Li, Xingya ^{[10
]}

Yu, Yan ^{[11
]}

Lai, Jinhuo ^{[12
]}

Yang, Huaping ^{[13
]}

Fang, Haohui ^{[14
]}

Chen, Hualin ^{[15
]}

Zhang, Peng ^{[16
]}

Gu, Kangsheng ^{[17
]}

Wang, Qiming ^{[18
]}

Shi, Jianhua ^{[19
]}

Yi, Tienan ^{[20
]}

Xu, Xingxiang ^{[21
]}

Ye, Xianwei ^{[22
]}

Wang, Daqing ^{[23
]}

Xie, Conghua ^{[24
]}

Liu, Chunling ^{[25
]}

Zheng, Yulong ^{[26
]}

Lin, Daren ^{[27
]}

Zhuang, Wu ^{[28
]}

Lu, Ping ^{[29
]}

Yu, Guohua ^{[30
]}

Li, Jinzhang ^{[31
]}

Gu, Yuhai ^{[32
]}

Li, Baolan ^{[33
]}

Wu, Rong ^{[34
]}

Jiang, Ou ^{[35
]}

Wang, Zaiyi ^{[36
]}

Wu, Guowu ^{[37
]}

Lin, Haifeng ^{[38
]}

Zhong, Diansheng ^{[39
]}

Xu, Yanhua ^{[40
]}

Shu, Yongqian ^{[41
]}

Wu, Di ^{[42
]}

Chen, Xingwu ^{[43
]}

Wang, Jie ^{[44
]}

Wang, Minghui ^{[45
]}

Yang, Runxiang ^{[46
]}

机构：

[1] Jilin Canc Hosp, Changchun, Peoples R China

[2] Hunan Canc Hosp, Changsha, Peoples R China

[3] Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China

[4] Shandong Univ, Shandong Canc Hosp & Inst, Jinan, Peoples R China

[5] Inner Mongolia Univ, Affiliated Hosp, Hohhot, Peoples R China

[6] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China

[7] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China

[8] Gansu Prov Canc Hosp, Lanzhou, Peoples R China

[9] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[10] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[11] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[12] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China

[13] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China

[14] Anhui Chest Hosp, Hefei, Peoples R China

[15] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China

[16] Shanghai Pulm Hosp, Shanghai, Peoples R China

[17] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China

[18] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[19] Linyi Canc Hosp, Linyi, Peoples R China

[20] Xiangyang Cent Hosp, Xiangyang, Peoples R China

[21] Northern Jiangsu Peoples Hosp, Yangzhou, Peoples R China

[22] Guizhou Prov Peoples Hosp, Guiyang, Peoples R China

[23] Hengshui Peoples Hosp, Hengshui, Peoples R China

[24] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China

[25] Xinjiang Med Univ, Canc Hosp, Urumqi, Peoples R China

[26] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[27] Jiangmen Cent Hosp, Jiangmen, Peoples R China

[28] Fujian Canc Hosp, Fuzhou, Peoples R China

[29] Xinxiang Med Coll, Affiliated Hosp 1, Xinxiang, Peoples R China

[30] Weifang Peoples Hosp, Weifang, Peoples R China

[31] Qinghai Univ, Affiliated Hosp, Xining, Peoples R China

[32] Qinghai Prov Peoples Hosp, Xining, Peoples R China

[33] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China

[34] China Med Univ, Shengjing Hosp, Shenyang, Peoples R China

[35] Second Peoples Hosp Neijiang, Neijiang, Peoples R China

[36] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi, Peoples R China

[37] Meizhou Peoples Hosp, Meizhou, Peoples R China

[38] Hainan Med Univ, Affiliated Hosp 2, Haikou, Peoples R China

[39] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China

[40] Jingzhou Cent Hosp, Jingzhou, Peoples R China

[41] Jiangsu Prov Hosp, Nanjing, Peoples R China

[42] Shenzhen Peoples Hosp, Shenzhen, Peoples R China

[43] Wannan Med Coll, Affiliated Hosp 1, Wuhu, Peoples R China

[44] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[45] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China

[46] Yunnan Canc Hosp, Kunming, Peoples R China

来源：

NATURE MEDICINE | 2024年 / 30卷 / 10期

关键词：

COMBINATION; SURVIVAL; EFFICACY; CRITERIA; TQB2450; IB;

D O I：

10.1038/s41591-024-03132-1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immunochemotherapy is the first-line standard for extensive-stage small-cell lung cancer (ES-SCLC). Combining the regimen with anti-angiogenesis may improve efficacy. ETER701 was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial that investigated the efficacy and safety of benmelstobart (a novel programmed death-ligand 1 (PD-L1) inhibitor) with anlotinib (a multi-target anti-angiogenic small molecule) and standard chemotherapy in treatment-naive ES-SCLC. The ETER701 trial assessed two primary endpoints: Independent Review Committee-assessed progression-free survival per RECIST 1.1 and overall survival (OS). Here the prespecified final progression-free survival and interim OS analysis is reported. Patients randomly received benmelstobart and anlotinib plus etoposide/carboplatin (EC; n = 246), placebo and anlotinib plus EC (n = 245) or double placebo plus EC ('EC alone'; n = 247), followed by matching maintenance therapy. Compared with EC alone, median OS was prolonged with benmelstobart and anlotinib plus EC (19.3 versus 11.9 months; hazard ratio 0.61; P = 0.0002), while improvement of OS was not statistically significant with anlotinib plus EC (13.3 versus 11.9 months; hazard ratio 0.86; P = 0.1723). The incidence of grade 3 or higher treatment-related adverse events was 93.1%, 94.3% and 87.0% in the benmelstobart and anlotinib plus EC, anlotinib plus EC, and EC alone groups, respectively. This study of immunochemotherapy plus multi-target anti-angiogenesis as first-line treatment achieved a median OS greater than recorded in prior randomized studies in patients with ES-SCLC. The safety profile was assessed as tolerable and manageable. Our findings suggest that the addition of anti-angiogenesis therapy to immunochemotherapy may represent an efficacious and safe approach to the management of ES-SCLC. ClinicalTrials.gov identifier: NCT04234607. In this triple-arm, placebo-controlled phase 3 trial, first-line treatment of patients with extensive-stage small-cell lung cancer with the anti-PD-L1 benmelstobart, tyrosine kinase inhibitor anlotinib and chemotherapy (CT) showed improved survival outcomes compared with anlotinib and CT or CT alone.

引用

页码：1819 / 1822

页数：19

共 29 条

[11] The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition [J].

Ou, Sai-Hong Ignatius ;

Zell, Jason A. .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) :300-310

[12] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study [J].

Kong, Tiandong ;

Chen, Lu ;

Zhao, Xiaoli ;

Duan, Fangfang ;

Zhou, Hanli ;

Wang, Lei ;

Liu, Danna .

INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) :1095-1105

[13]

Lee WS, 2020, EXP MOL MED, V52, P1475

[14] Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy [J].

Li, Tian ;

Qiao, Tianyun .

SEMINARS IN CANCER BIOLOGY, 2022, 86 :117-125

[15] Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma [J].

Liu, Jiayong ;

Gao, Tian ;

Tan, Zhichao ;

Li, Shu ;

Xu, Jie ;

Bai, Chujie ;

Xue, Ruifeng ;

Xie, Lu ;

Zhang, Lu ;

Fan, Zhengfu ;

Guo, Wei .

CLINICAL CANCER RESEARCH, 2022, 28 (16) :3473-3479

[16] Sintilimab plus chemotherapy for patients with EGFR- mutated non-squamous non-small-cell lung cancer with disease progression after EGFRtyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double- blind, randomised, placebo-controlled, phase 3 trial [J].

Lu, Shun ;

Wu, Lin ;

Jian, Hong ;

Cheng, Ying ;

Wang, Qiming ;

Fang, Jian ;

Wang, Ziping ;

Hu, Yanping ;

Han, Liang ;

Sun, Meili ;

Miao, Liyun ;

Ding, Cuimin ;

Cui, Jiuwei ;

Wang, Ke ;

Li, Baolan ;

Li, Xingya ;

Ye, Feng ;

Liu, Anwen ;

Pan, Yueyin ;

Cang, Shundong ;

Zhou, Hui ;

Sun, Xing ;

Shen, Yuping ;

Wang, Shuyan ;

Zhang, Wen ;

He, Yue .

LANCET RESPIRATORY MEDICINE, 2023, 11 (07) :624-636

[17] Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J].

Paz-Ares, Luis ;

Dvorkin, Mikhail ;

Chen, Yuanbin ;

Reinmuth, Niels ;

Hotta, Katsuyuki ;

Trukhin, Dmytro ;

Statsenko, Galina ;

Hochmair, Maximilian J. ;

Ozguroglu, Mustafa ;

Ji, Jun Ho ;

Voitko, Oleksandr ;

Poltoratskiy, Artem ;

Ponce, Santiago ;

Verderame, Francesco ;

Havel, Libor ;

Bondarenko, Igor ;

Kazarnowicz, Andrzej ;

Losonczy, Gyorgy ;

Conev, Nikolay V. ;

Armstrong, Jon ;

Byrne, Natalie ;

Shire, Norah ;

Jiang, Haiyi ;

Goldman, Jonathan W. ;

Batagelj, Emilio ;

Casarini, Ignacio ;

Pastor, Anea Viviana ;

Sena, Susana Noemi ;

Zarba, Juan Jose ;

Burghuber, Otto ;

Hartl, Sylvia ;

Hochmair, Maximilian J. ;

Lamprecht, Bernd ;

Studnicka, Michael ;

Schlittler, Luis Alberto ;

de Oliveira, Fabricio Augusto Martinelli ;

Calabrich, Aknar ;

Girotto, Gustavo Colagiovanni ;

Dos Reis, Peo ;

Gorini, Carlos Fausto Nino ;

De Marchi, Peo Rafael Martins ;

Baldotto, Clarissa Serodio da Rocha ;

Sette, Claudia ;

Zukin, Mauro ;

Conev, Nikolay V. ;

Dudov, Assen ;

Ilieva, Rumyana ;

Koynov, Krassimir ;

Krasteva, Rositsa ;

Tonev, Ivan .

LANCET, 2019, 394 (10212) :1929-1939

[18] Small-cell lung cancer [J].

Rudin, Charles M. ;

Brambilla, Elisabeth ;

Faivre-Finn, Corinne ;

Sage, Julien .

NATURE REVIEWS DISEASE PRIMERS, 2021, 7 (01)

[19] iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J].

Seymour, Lesley ;

Bogaerts, Jan ;

Perrone, Andrea ;

Ford, Robert ;

Schwartz, Lawrence H. ;

Mandrekar, Sumithra ;

Lin, Nancy U. ;

Litiere, Saskia ;

Dancey, Janet ;

Chen, Alice ;

Hodi, F. Stephen ;

Therasse, Patrick ;

Hoekstra, Otto S. ;

Shankar, Lalitha K. ;

Wolchok, Jedd D. ;

Ballinger, Marcus ;

Caramella, Caroline ;

de Vries, Elisabeth G. E. .

LANCET ONCOLOGY, 2017, 18 (03) :E143-E152

[20] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

← 1 2 3 →